Find a news story anywhere in the world:

Category:    

Keywords:   

Address:    
   
Stories Stories Health Allergy drug firm Circassia seeks $285 million in London IPO

Allergy drug firm Circassia seeks $285 million in London IPO

http://mireportz.com/media/reviews/photos/thumbnail/300x300s/02/ff/ea/10797-allergy-drug-firm-circassia-seeks-285-million-in-london-ipo-71-1398497745.gif
Written by Aldine      April 26, 2014    
 
0.0 (0)
501   0   3   0   0   0
 
Write Review
Allergy drug firm Circassia seeks $285 million in London IPO.gif

Circassia, a company developing allergy treatments based on a discovery by scientists at Imperial College in London, plans to raise about 175 million pounds ($285 million) of new funds in a stock market debut to bring its cat allergy vaccine to market.

 Allergy drug firm Circassia seeks $285 million in London IPO

Chief executive and co-founder Steve Harris said the proceeds of the flotation in London, one of the biggest ever in the biopharmaceutical sector, would also help the firm's programs in other common allergies such as house dust mites, grass and ragweed.

The company had already received 105 million pounds of funding from investors including Imperial Innovations, which holds just under 20 percent, Goldman Sachs, Invesco Perpetual and Lansdowne Partners, he said.

[Read Full article: Allergy drug firm Circassia seeks $285 million in London IPO]

Allergy drug firm Circassia seeks $285 million in London IPO-1.jpg
Allergy drug firm Circassia seeks $285 million in London IPO-2.jpg

Location

Epicentre
London,London,United Kingdom

Details

Author
Paul Sandle
Contributor's Comment
Circassia, a company developing allergy treatments based on a discovery by scientists at Imperial College in London.
Swap Start/End

User reviews

There are no user reviews for this listing.

 
Site sponsored by BiStuff | Buy & Sell Locally